Advicenne SA

ADVICENNE S.A. is a late-stage biopharmaceutical company based in France. The Company focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company's medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
  • TickerADVIC
  • ISINFR0013296746
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance


Anita Ye ...
  • Dylan van Haaften

Renal capital markets activity drawing awareness for Acidosis and Renal indications

Anita Ye ...
  • Dylan van Haaften

Head-to-head; acid to asset

GlobalData Department

Advicenne SA (ADVIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Advicenne SA (Advicenne) is a developer of pediatric medicines. The company offers product portfolio such as ADV6209, a liquid formulation of a benzodiazepine for moderate sedation and anesthetic premedication; ADV7103, a formulation in the form of micro-tablets for renal tubulopathies. It provides its products for the treatment of neurological diseases and renal disorders in children. Advicenne also offers products for the treatment epilepsy, anesthesia and dystonia. The company offers clinical research services by using statistical tools, approaches of meta-analysis and data modelin...

Anaïs Dudout

Proxy Report - 19/06/2018

Pour sa première assemblée générale annuelle en temps que société côtée, Proxinvest alerte Advicenne sur plusieurs éléments de gouvernance sur lesquels nous avons des réserves. Même si Advicenne est très contrôlée, le conseil d'administration n'est composée que d'administrateurs non libres de conflits d'intérêts, ce qui n'est pas acceptable et bien en deça des standards de la place financière. Nous notons que la société s'est engagée à diversifier son conseil d'administration (qui n'est également composé que de deux femmes et d'un membre non national) et nous espérons qu'elle tiendra sa prome...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch